Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 509
- Registration Number
- NCT00550095
- Locations
- 🇪🇬
Novartis Investigative Site ,, Cairo, Egypt
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1334
- Registration Number
- NCT00549770
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 229
- Registration Number
- NCT00523549
- Locations
- 🇺🇸
Novartis Investigative Sites, USA, New Jersey, United States
Preventing Microalbuminuria in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2019-09-06
- Target Recruit Count
- 612
- Registration Number
- NCT00503152
- Locations
- 🇮🇹
Hospital "Casa Sollievo della Sofferenza" - Division of Endocrinology, San Giovanni Rotondo, Foggia, Italy
🇮🇹Azienda USL 2, Olbia, Italy
🇮🇹Hospital "Azienda Ospedaliera di Treviglio e Caravaggio" - Diabetologic Ambulatory of Ponte San Pietro, Ponte San Pietro, Bergamo, Italy
Preventing ESRD in Overt Nephropathy of Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2016-06-01
- Target Recruit Count
- 102
- Registration Number
- NCT00494715
- Locations
- 🇮🇹
Clinical Research Center for Rare Diseases "Aldo e Cele Daccò", Ranica, Bergamo, Italy
🇮🇹Hospital " Casa Sollievo della Sofferenza" - Unit of Nephrology, San Giovanni Rotondo, Foggia, Italy
🇮🇹University - AUSL 1 - Institute of Medical Pathology, Sassari, Italy
A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT00457626
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 250
- Registration Number
- NCT00446511
- Locations
- 🇫🇷
Sites in France, France, France
🇮🇳Sites in India, India, India
🇵🇱Sites in Poland, Poland, Poland
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
- Conditions
- Interventions
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00446563
- Locations
- 🇩🇪
25 centers in Germany, Ludwigshafen, Germany
Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00433836
- Locations
- 🇮🇹
Sites in Italy, Sites in Italy, Italy
🇫🇷Sites in France, Sites in France, France
🇸🇪Sites in Sweden, Sites in Sweden, Sweden
A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT00426348
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.